Loading…
GEDEFO-SEFH management of antineoplastic extravasations survey results
Introduction Extravasation is a potentially severe complication of intravenous administration of antineoplastic drugs. The limited data makes it difficult to develop an optimal management scheme. The objective of this study is to describe the clinical practice in the extravasation management of anti...
Saved in:
| Published in: | Journal of oncology pharmacy practice 2024-01, Vol.30 (1), p.67-77 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c320t-8e854f36eb64f5c69fc915176d47d8e376e2ecb8cf154f82f32929b2e95a8bca3 |
| container_end_page | 77 |
| container_issue | 1 |
| container_start_page | 67 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 30 |
| creator | Jiménez-Pulido, Inmaculada Albert-Marí, María Asunción Conde-Estévez, David San José-Ruiz, Begoña Gil-Lemus, María Ángeles Cercós-LLetí, Ana Cristina Esteban-Mensua, María Jesús Díaz-Carrasco, María Sacramento |
| description | Introduction
Extravasation is a potentially severe complication of intravenous administration of antineoplastic drugs. The limited data makes it difficult to develop an optimal management scheme. The objective of this study is to describe the clinical practice in the extravasation management of antineoplastic agents in Spanish centers.
Methods
An online survey was distributed to oncology pharmacists using the email distribution list of the Spanish Society of Hospital Pharmacists. Respondents were surveyed on the standard operational protocol (SOP) of extravasation, tissue damage risk classification, and specific measures of extravasation management.
Results
A total of 68 surveys were completed. A specific extravasation SOP was available in 82.4% centers. The pharmacist participates in the authorship (100%) and actively collaborates in extravasation management (76.5%). A tissue damage risk classification based on the three categories was mostly adopted (48.2%) and 73.2% applied specific criteria based on concentration and/or extravasated volume. Extravasation management was mainly performed with the application of physical measures and/or antidotes (91.2%). High variability in the choices of pharmacological and/or physical measures recommended is outstanding.
Conclusion
The results of this study highlight the involvement of Spanish pharmacists in extravasation management, the application of physical measures and/or pharmacological measures as the method of choice in extravasation management, as well as the existing discrepancies in tissue damage risk classification and management recommendations |
| doi_str_mv | 10.1177/10781552231167873 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2799170636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_10781552231167873</sage_id><sourcerecordid>2918161268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-8e854f36eb64f5c69fc915176d47d8e376e2ecb8cf154f82f32929b2e95a8bca3</originalsourceid><addsrcrecordid>eNp1kEtLxDAUhYMoOj5-gBspuHFTzU3aPJaiHUcYmIUK7kqauZVKH2OSDvrvjYwPUFzdC_c75x4OIcdAzwGkvAAqFeQ5YxxASCX5FplAJmVKNXvcjnu8px_AHtn3_plSqiRTu2SPS8pZJmFCpjfFdTFdpHfFdJZ0pjdP2GEfkqFOTB-aHodVa3xobIKvwZm18SY0Q-8TP7o1viUO_dgGf0h2atN6PPqcB-RhWtxfzdL54ub26nKeWs5oSBWqPKu5wEpkdW6Frq2GHKRYZnKpkEuBDG2lbA2RU6zmTDNdMdS5UZU1_ICcbXxXbngZ0Yeya7zFtjUx6ehLJrUGSQUXET39hT4Po-tjupJpUCCACRUp2FDWDd47rMuVazrj3kqg5UfJ5Z-So-bk03msOlx-K75ajcD5BvCxzp-3_zu-A-magwk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918161268</pqid></control><display><type>article</type><title>GEDEFO-SEFH management of antineoplastic extravasations survey results</title><source>Sage Journals Online</source><creator>Jiménez-Pulido, Inmaculada ; Albert-Marí, María Asunción ; Conde-Estévez, David ; San José-Ruiz, Begoña ; Gil-Lemus, María Ángeles ; Cercós-LLetí, Ana Cristina ; Esteban-Mensua, María Jesús ; Díaz-Carrasco, María Sacramento</creator><creatorcontrib>Jiménez-Pulido, Inmaculada ; Albert-Marí, María Asunción ; Conde-Estévez, David ; San José-Ruiz, Begoña ; Gil-Lemus, María Ángeles ; Cercós-LLetí, Ana Cristina ; Esteban-Mensua, María Jesús ; Díaz-Carrasco, María Sacramento</creatorcontrib><description>Introduction
Extravasation is a potentially severe complication of intravenous administration of antineoplastic drugs. The limited data makes it difficult to develop an optimal management scheme. The objective of this study is to describe the clinical practice in the extravasation management of antineoplastic agents in Spanish centers.
Methods
An online survey was distributed to oncology pharmacists using the email distribution list of the Spanish Society of Hospital Pharmacists. Respondents were surveyed on the standard operational protocol (SOP) of extravasation, tissue damage risk classification, and specific measures of extravasation management.
Results
A total of 68 surveys were completed. A specific extravasation SOP was available in 82.4% centers. The pharmacist participates in the authorship (100%) and actively collaborates in extravasation management (76.5%). A tissue damage risk classification based on the three categories was mostly adopted (48.2%) and 73.2% applied specific criteria based on concentration and/or extravasated volume. Extravasation management was mainly performed with the application of physical measures and/or antidotes (91.2%). High variability in the choices of pharmacological and/or physical measures recommended is outstanding.
Conclusion
The results of this study highlight the involvement of Spanish pharmacists in extravasation management, the application of physical measures and/or pharmacological measures as the method of choice in extravasation management, as well as the existing discrepancies in tissue damage risk classification and management recommendations</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/10781552231167873</identifier><identifier>PMID: 37032471</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Antidotes ; Antineoplastic drugs ; Classification ; Disease management ; Extravasation ; Intravenous administration ; Pharmacists ; Surveys</subject><ispartof>Journal of oncology pharmacy practice, 2024-01, Vol.30 (1), p.67-77</ispartof><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c320t-8e854f36eb64f5c69fc915176d47d8e376e2ecb8cf154f82f32929b2e95a8bca3</cites><orcidid>0000-0003-3488-5444 ; 0000-0002-9414-9409 ; 0000-0001-9043-8513 ; 0000-0002-3814-2341</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924,79135</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37032471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiménez-Pulido, Inmaculada</creatorcontrib><creatorcontrib>Albert-Marí, María Asunción</creatorcontrib><creatorcontrib>Conde-Estévez, David</creatorcontrib><creatorcontrib>San José-Ruiz, Begoña</creatorcontrib><creatorcontrib>Gil-Lemus, María Ángeles</creatorcontrib><creatorcontrib>Cercós-LLetí, Ana Cristina</creatorcontrib><creatorcontrib>Esteban-Mensua, María Jesús</creatorcontrib><creatorcontrib>Díaz-Carrasco, María Sacramento</creatorcontrib><title>GEDEFO-SEFH management of antineoplastic extravasations survey results</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Introduction
Extravasation is a potentially severe complication of intravenous administration of antineoplastic drugs. The limited data makes it difficult to develop an optimal management scheme. The objective of this study is to describe the clinical practice in the extravasation management of antineoplastic agents in Spanish centers.
Methods
An online survey was distributed to oncology pharmacists using the email distribution list of the Spanish Society of Hospital Pharmacists. Respondents were surveyed on the standard operational protocol (SOP) of extravasation, tissue damage risk classification, and specific measures of extravasation management.
Results
A total of 68 surveys were completed. A specific extravasation SOP was available in 82.4% centers. The pharmacist participates in the authorship (100%) and actively collaborates in extravasation management (76.5%). A tissue damage risk classification based on the three categories was mostly adopted (48.2%) and 73.2% applied specific criteria based on concentration and/or extravasated volume. Extravasation management was mainly performed with the application of physical measures and/or antidotes (91.2%). High variability in the choices of pharmacological and/or physical measures recommended is outstanding.
Conclusion
The results of this study highlight the involvement of Spanish pharmacists in extravasation management, the application of physical measures and/or pharmacological measures as the method of choice in extravasation management, as well as the existing discrepancies in tissue damage risk classification and management recommendations</description><subject>Antidotes</subject><subject>Antineoplastic drugs</subject><subject>Classification</subject><subject>Disease management</subject><subject>Extravasation</subject><subject>Intravenous administration</subject><subject>Pharmacists</subject><subject>Surveys</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kEtLxDAUhYMoOj5-gBspuHFTzU3aPJaiHUcYmIUK7kqauZVKH2OSDvrvjYwPUFzdC_c75x4OIcdAzwGkvAAqFeQ5YxxASCX5FplAJmVKNXvcjnu8px_AHtn3_plSqiRTu2SPS8pZJmFCpjfFdTFdpHfFdJZ0pjdP2GEfkqFOTB-aHodVa3xobIKvwZm18SY0Q-8TP7o1viUO_dgGf0h2atN6PPqcB-RhWtxfzdL54ub26nKeWs5oSBWqPKu5wEpkdW6Frq2GHKRYZnKpkEuBDG2lbA2RU6zmTDNdMdS5UZU1_ICcbXxXbngZ0Yeya7zFtjUx6ehLJrUGSQUXET39hT4Po-tjupJpUCCACRUp2FDWDd47rMuVazrj3kqg5UfJ5Z-So-bk03msOlx-K75ajcD5BvCxzp-3_zu-A-magwk</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Jiménez-Pulido, Inmaculada</creator><creator>Albert-Marí, María Asunción</creator><creator>Conde-Estévez, David</creator><creator>San José-Ruiz, Begoña</creator><creator>Gil-Lemus, María Ángeles</creator><creator>Cercós-LLetí, Ana Cristina</creator><creator>Esteban-Mensua, María Jesús</creator><creator>Díaz-Carrasco, María Sacramento</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3488-5444</orcidid><orcidid>https://orcid.org/0000-0002-9414-9409</orcidid><orcidid>https://orcid.org/0000-0001-9043-8513</orcidid><orcidid>https://orcid.org/0000-0002-3814-2341</orcidid></search><sort><creationdate>202401</creationdate><title>GEDEFO-SEFH management of antineoplastic extravasations survey results</title><author>Jiménez-Pulido, Inmaculada ; Albert-Marí, María Asunción ; Conde-Estévez, David ; San José-Ruiz, Begoña ; Gil-Lemus, María Ángeles ; Cercós-LLetí, Ana Cristina ; Esteban-Mensua, María Jesús ; Díaz-Carrasco, María Sacramento</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-8e854f36eb64f5c69fc915176d47d8e376e2ecb8cf154f82f32929b2e95a8bca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antidotes</topic><topic>Antineoplastic drugs</topic><topic>Classification</topic><topic>Disease management</topic><topic>Extravasation</topic><topic>Intravenous administration</topic><topic>Pharmacists</topic><topic>Surveys</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiménez-Pulido, Inmaculada</creatorcontrib><creatorcontrib>Albert-Marí, María Asunción</creatorcontrib><creatorcontrib>Conde-Estévez, David</creatorcontrib><creatorcontrib>San José-Ruiz, Begoña</creatorcontrib><creatorcontrib>Gil-Lemus, María Ángeles</creatorcontrib><creatorcontrib>Cercós-LLetí, Ana Cristina</creatorcontrib><creatorcontrib>Esteban-Mensua, María Jesús</creatorcontrib><creatorcontrib>Díaz-Carrasco, María Sacramento</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiménez-Pulido, Inmaculada</au><au>Albert-Marí, María Asunción</au><au>Conde-Estévez, David</au><au>San José-Ruiz, Begoña</au><au>Gil-Lemus, María Ángeles</au><au>Cercós-LLetí, Ana Cristina</au><au>Esteban-Mensua, María Jesús</au><au>Díaz-Carrasco, María Sacramento</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GEDEFO-SEFH management of antineoplastic extravasations survey results</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2024-01</date><risdate>2024</risdate><volume>30</volume><issue>1</issue><spage>67</spage><epage>77</epage><pages>67-77</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Introduction
Extravasation is a potentially severe complication of intravenous administration of antineoplastic drugs. The limited data makes it difficult to develop an optimal management scheme. The objective of this study is to describe the clinical practice in the extravasation management of antineoplastic agents in Spanish centers.
Methods
An online survey was distributed to oncology pharmacists using the email distribution list of the Spanish Society of Hospital Pharmacists. Respondents were surveyed on the standard operational protocol (SOP) of extravasation, tissue damage risk classification, and specific measures of extravasation management.
Results
A total of 68 surveys were completed. A specific extravasation SOP was available in 82.4% centers. The pharmacist participates in the authorship (100%) and actively collaborates in extravasation management (76.5%). A tissue damage risk classification based on the three categories was mostly adopted (48.2%) and 73.2% applied specific criteria based on concentration and/or extravasated volume. Extravasation management was mainly performed with the application of physical measures and/or antidotes (91.2%). High variability in the choices of pharmacological and/or physical measures recommended is outstanding.
Conclusion
The results of this study highlight the involvement of Spanish pharmacists in extravasation management, the application of physical measures and/or pharmacological measures as the method of choice in extravasation management, as well as the existing discrepancies in tissue damage risk classification and management recommendations</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>37032471</pmid><doi>10.1177/10781552231167873</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-3488-5444</orcidid><orcidid>https://orcid.org/0000-0002-9414-9409</orcidid><orcidid>https://orcid.org/0000-0001-9043-8513</orcidid><orcidid>https://orcid.org/0000-0002-3814-2341</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2024-01, Vol.30 (1), p.67-77 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2799170636 |
| source | Sage Journals Online |
| subjects | Antidotes Antineoplastic drugs Classification Disease management Extravasation Intravenous administration Pharmacists Surveys |
| title | GEDEFO-SEFH management of antineoplastic extravasations survey results |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T02%3A12%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GEDEFO-SEFH%20management%20of%20antineoplastic%20extravasations%20survey%20results&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Jim%C3%A9nez-Pulido,%20Inmaculada&rft.date=2024-01&rft.volume=30&rft.issue=1&rft.spage=67&rft.epage=77&rft.pages=67-77&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/10781552231167873&rft_dat=%3Cproquest_cross%3E2918161268%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c320t-8e854f36eb64f5c69fc915176d47d8e376e2ecb8cf154f82f32929b2e95a8bca3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2918161268&rft_id=info:pmid/37032471&rft_sage_id=10.1177_10781552231167873&rfr_iscdi=true |